Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,591.90
(
0.54%
)
US TECH 100
23,496.00
(
0.59%
)
Dow Jones
46,429.49
(
0.66%
)
Brent Oil
98.78
(
2.36%
)
Bitcoin
70,946.99
(
0.61%
)
News Focus
News Focus
Post# of 257285
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122810
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 191287

Tuesday, 05/19/2015 8:58:06 AM

Tuesday, May 19, 2015 8:58:06 AM

Post# of 257285
EGRX receives US patent on rapid-infusion formulation of Treanda:

http://finance.yahoo.com/news/patent-issued-eagle-pharmaceuticals-bendamustine-123000408.html

Eagle Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S. Patent No. 9,034,908, which pertains to the use of the bendamustine hydrochloride (HCl) formulation administered in a 50mL bag within ten minutes (the “rapid infusion” product). The patent issued today expires in March 2033.

This is the product that Teva licensed in Feb 2015 (#msg-110943484). The product has a PDUFA date of 12/13/15.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today